admin Moderna’s COVID-19 vaccine sales pushes to nearly USD 7 billion in the final quarter of 2021, and the drugmaker says it has signed purchase agreements for another USD 19 billion in sales this year. The vaccine maker’s COVID-19 shots, which are now available in more than 70 countries, totalled USD 17.7 billion in sales last year, their first full year on the market. Moderna’s COVID-19 vaccine is the only product the drugmaker has on the market.
Recently, U.S. regulators gave full approval to the vaccine, which is now being marketed under the name Spikevax. But the company is still waiting for U.S. regulators to authorise the vaccine’s use in 12- to 17-year-olds, however few other countries have authorised that expanded use. Regulators are studying the rare risk of a heart inflammation that has shown up in some people who have received the shots. 75mn + people have become fully vaccinated with Moderna’s shot in the United States since its emergency authorisation over a year ago, according to the Centers for Disease Control and Prevention. Another 40 million have received booster doses. In the recently completed fourth quarter, Moderna gained USD 4.87 billion on USD 7.21 billion in revenue, while getting per share came to USD 11.29. Analysts expect, on average, earnings of USD 9.96 per share on USD 6.8 billion in revenue, stated FactSet. For the full year, Moderna brought USD 12.2 bn, compared to a net loss of USD 747 mn in 2020. For this year, the Cambridge, Massachusetts company informed in November it expects revenue between USD 17 billion and USD 22 billion. Analysts forecast USD 21.5 billion in revenue.
Its purchase agreements for the new year include an additional USD 3 billion in options for any potential updated vaccine boosters. Shares of Moderna Inc. tumbled more than 6% in premarket trading. Broader U.S. trading indexes dropped more than 2% after Russia launched a military attack on Ukraine, as per the company stated on Thursday.
Magazine 
